ADAM19
ADAM19 (ADAM metallopeptidase domain 19, previously meltrin beta or MLTNB) is a membrane-anchored metalloproteinase of the ADAM family. It processes beta-type neuregulin isoforms and is linked to neurogenesis, synaptogenesis and bone biology. Browse Assay Genie's current range of ADAM19 research reagents below, or read on for the biology behind the target.
ADAM19 participates in the proteolytic processing of beta-type neuregulin isoforms, which are involved in neurogenesis and synaptogenesis, suggesting a regulatory role in glial cells. It also cleaves alpha-2 macroglobulin, and it may contribute to osteoblast differentiation and/or osteoblast activity in bone. It has been shown to be an active metalloproteinase, and it may take part in normal physiological processes such as cell migration, cell adhesion, cell-cell and cell-matrix interactions, and signal transduction.
The ADAM19 gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins. They have been implicated in biological processes involving cell-cell and cell-matrix interactions, including fertilisation, muscle development and neurogenesis. The ADAM19 protein is a type I transmembrane protein and serves as a marker for dendritic cell differentiation. The mouse ortholog is Adam19.
The protein was formerly named a disintegrin and metalloproteinase domain 19 (meltrin beta), with MLTNB as a previous symbol. HGNC places it in the ADAM metallopeptidase domain containing gene group. ADAM19 is proposed to play a role in pathological processes such as cancer, inflammatory diseases, renal diseases and Alzheimer's disease, which makes it a topic of interest for researchers studying protease-driven signalling and tissue remodelling. Researchers working with the ADAM19 antibody, ADAM19 ELISA kit or ADAM19 protein can place their findings in this context.
ADAM19 takes part in proteolytic processing of beta-type neuregulin isoforms, making it relevant to studies of neurogenesis and synaptogenesis.
Its role in neuregulin cleavage suggests a regulatory function in glial cells, a focus for neural signalling research.
ADAM19 may be involved in osteoblast differentiation and activity in bone, supporting work on skeletal cell biology.
ADAM19 is proposed to contribute to cancer, inflammatory and renal diseases and Alzheimer's disease, and marks dendritic cell differentiation.
ADAM19 is a membrane-anchored metalloproteinase that participates in the proteolytic processing of beta-type neuregulin isoforms involved in neurogenesis and synaptogenesis. It also cleaves alpha-2 macroglobulin and may be involved in osteoblast differentiation and activity in bone.
ADAM19 stands for ADAM metallopeptidase domain 19. It was previously named a disintegrin and metalloproteinase domain 19 (meltrin beta), with MLTNB as an earlier symbol. UniProt lists the protein as disintegrin and metalloproteinase domain-containing protein 19.
ADAM19 is proposed to play a role in cancer, inflammatory diseases, renal diseases and Alzheimer's disease. A mouse ortholog, Adam19, exists. Check the datasheet of any product for its validated reactivity.
Other ADAM family metalloproteinases and related ADAMTS proteases with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9H013; product specifications from Assay Genie datasheets.